Short Interest in NuCana plc (NASDAQ:NCNA) Drops By 15.7%

NuCana plc (NASDAQ:NCNA) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 121,700 shares, a drop of 15.7% from the December 31st total of 144,300 shares. Currently, 3.3% of the company’s shares are short sold. Based on an average daily trading volume, of 149,300 shares, the days-to-cover ratio is currently 0.8 days.

NuCana Stock Performance

Shares of NCNA stock traded down $0.01 during trading hours on Friday, hitting $1.02. 135,153 shares of the company were exchanged, compared to its average volume of 89,415. The firm has a market cap of $2.69 million, a P/E ratio of -0.10 and a beta of 0.97. NuCana has a fifty-two week low of $0.85 and a fifty-two week high of $19.41. The company has a 50 day simple moving average of $1.21 and a two-hundred day simple moving average of $2.44.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings data on Monday, November 25th. The company reported ($2.28) EPS for the quarter, topping the consensus estimate of ($3.49) by $1.21. As a group, sell-side analysts expect that NuCana will post -12.86 EPS for the current fiscal year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.